The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension
Summary The presence of slightly increased urinary albumin excretion ( UAE ) , even at levels well below levels detectable by an ordinary dipstick , has been suggested as a predictor of cardiovascular morbidity and as a reflection of the degree of overall vascular permeability . The aim of the present investigation was to study the effects of two different antihypertensive drug regimens , an ACE inhibitor and aβ-adrenoceptor antagonist , on the low UAE rate observed in subjects with uncomplicated , mild to moderate primary hypertension . After a 4-week placebo run-in period , 49 patients ( mean age 54 y ) were r and omly assigned in a double blind manner either to further 4 weeks on placebo ( P , n = 15 ) , 8 weeks on lisinopril ( L , n = 17 ; 20 mg/40 mg o. d. ) or 8 weeks on atenolol ( A , n = 17 ; 50 mg/100 mg o. d. ) . The 24-h UAE was measured every second week . At entry and after 4 weeks the glomerular filtration rate and the renal plasma flow were measured . Both drugs lowered blood pressure ( BP ) to a similar extent after 4 and 8 weeks of treatment ; the blood pressures were 160/106 ( P ) , 159/104 ( L ) and 154/103 ( A ) at entry , and 133/83 ( L ) and 134/87 ( A ) at the end of the study after 8 weeks . On entry the 24-h UAE in all patients ranged from 4 to 49 mg ( mean 14.1 mg ) , and it did not differ significantly between groups . After 4 weeks the UAE during 24 h was reduced by approximately one third in the lisinopril-treated group , and by 10 % in the atenolol reated group , whereas it remained unaltered in the group on placebo . After 8 weeks the 24-hour UAE was approximately 20 % lower compared to baseline levels in the lisinopril-treated patients . In the atenolol-treated group the UAE was unaltered compared to baseline . However , none of the changes in the UAE was statistically significant , nor were there any statistically significant differences between the two antihypertensive regimens . Moreover , there were no significant effect of the lisinopril or atenolol  treatment on renal function or on renal haemodynamics . It is concluded that in patients with uncomplicated , mild to moderate hypertension both an ACE-inhibitor , such as lisinopril , as well as aβ1-selective adrenoceptor blocking agent , such as
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .